

**REMARKS**

Claims 1-117 are pending in this application. Claims 1-20 and 25-26 are pending on the merits upon entry of this paper. Claims 4-5, 8-11, 13-20 and 25-26 have been amended to be proper dependant claims. Claims 25-26 have been amended to improve clarity. Support for the amendments can be found in the specification as filed. Claims 21-24 and 27-117 have been withdrawn without prejudice or disclaimer. Applicants reserve the right to file one or more divisional or continuation applications directed to any withdrawn subject matter should the withdrawn claims not be rejoined. No new matter is added.

In response to the Restriction Requirement, Applicants hereby elect:

Group (I) directed to claims 1-20 and 25-26, drawn to a method for quantitating a biological molecule.

It is respectfully submitted that all claims are now in condition for allowance, early notice of which would be appreciated. Should the Examiner disagree, Applicants respectfully request a telephonic or in-person interview with the undersigned attorney to discuss any remaining issues and to expedite the eventual allowance of the claims.

Except for issues payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310.

Respectfully submitted,

Date: June 26, 2009

By /Mark Sullivan/  
Mark J. Sullivan  
Reg.. No. 54,478

**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. (202) 739-3000  
Fax. (202) 739-3001